 |
|
|
| |
Therapeutic drug monitoring of daclatasvir in HIV/HCV co-infected patients receiving darunavir/ritonavir 800/100mg once-daily
|
| |
| |
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 26-28, 2015, Washington, DC
Desnoyer A1, Le MP1, Belissa E1, Pain J-B1, Gervais A2, Chas J3, Valantin MA4, Perré Ph5, Salmon-Céron D6, Dominguez S7, Larrouy L8, Yazdanpanah Y2, Peytavin G1,8
1APHP, Bichat-Claude Bernard Hospital, Clinical Pharmaco-Toxicology Department, 2APHP, Bichat-Claude Bernard Hospital, Infectious Diseases & Tropical Department, Paris, France, 3APHP, Tenon Hospital, Infectious Diseases & Tropical Department, Paris, France, 4APHP, Pitié-Salpétrière Hospital, Infectious Diseases & Tropical Department, APHP, Paris, France, 5CHD Vendée, Internal Medicine Department, La Roche sur Yon, France, 6APHP, Cochin Hospital, Internal Medicine Department, Paris, France, 7APHP, Henri Mondor Hospital, Clinical Immunology Department, Créteil, France, 8APHP, Bichat-Claude Bernard Hospital, Virology Department, Paris, France, 9IAME, UMR 1137, INSERM, Paris, France
Corresponding author: Dr Desnoyer A, audedesnoyer@gmail.com, Laboratoire de Pharmaco-Toxicologie, APHP, Groupe Hospitalier Bichat-Claude Bernard, 46 rue Henri Huchard, 75018 Paris, Tel: +33 1 40 25 84 54
|
| |
|
|
|
|
|
